Similar Items: Real-world effectiveness and safety of CGRP monoclonal antibodies in elderly migraine patients: a Korean multicenter study
- CGRP-targeted migraine treatment and early pathophysiology in experimental subarachnoid hemorrhage
- Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond
- Sex-dependent central amygdala physiology after supradural CGRP exposure is associated with migraine-like behaviors
- Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry
- Consistency of response to rimegepant for the acute treatment of migraine among real-world users – findings from the prospective observational CONFIDENCE study
- CGRP-provoked headache is associated with a neuroimmune signature in idiopathic intracranial hypertension